How is In-Vitro Diagnostics Revolutionizing Clinical Analysis?
In-vitro diagnostics can detect early warning signs and individual risk factors, creating new opportunities for prevention and early intervention.
FREMONT, CA: Long gone are the days when doctors and physicians used to collect blood samples for examining functional abnormalities. With the advancing medical technology, a unique transition occurred in the field of in-vitro diagnostics, making it a more efficient and effortless process for patients and doctors. The idea of medical devices and accessories to test and detect health anomalies by examining body fluids set a new milestone for traditional diagnostics companies. Presently, the devices have become so refined that it can even perform an intricate analysis of DNA technology. From simple calibration to sophisticated reagent control, the in-vitro diagnostics platform has shown un-substitutable importance in providing safety to patients.
As the in-vitro diagnostics produces effective, logical, and cost-efficient processes, the demand for utilizing in-vitro clinical analysis in the healthcare market skyrockets. Diagnostics testing with its precise and comparative study is proving to impact the scientific outcomes directly.
Market Growth for Cannabis Testing Equipment
The cannabis industry has come a long way from lingering in the black market to open market sales to; it still is in an embryonic stage. However, even with the limited involvement has given rise to a wide range of new applications. Various in-vitro diagnostics instruments ranging from gas chromatography, thin-layer liquid chromatography, X-ray diffraction spectroscopy, and many more are employed for performing heavy metal testing and safety testing.
Liquid Biopsy up on the rise
In present years, liquid biopsy has created a tremendous buzz in the clinical healthcare market. However, there are specific difficulties with collecting relevant samples from patients and error correction, which needs immediate fixing. In spite of a long road ahead with these challenges, their usefulness still shines in the field of cancer treatment.
Liquid biopsy eliminates false negatives when compounded with some imaging tests. A study published in Translational Oncology demonstrated that by combining liquid biopsy and radiology imaging will enable visualization of clonal redistribution as well as RAS mutation during therapy with anti-EGFR mAb indicating resistance.
By Tom Farrah, CIO & SVP, Dr Pepper Snapple Group
By George Evans, CIO, Singing River Health System
By John Kamin, EVP and CIO, Old National Bancorp
By Phil Jordan, CIO, Telefonica
By Elliot Garbus, VP-IoT Solutions Group & GM-Automotive...
By Dennis Hodges, CIO, Inteva Products
By Bill Krivoshik, SVP & CIO, Time Warner Inc.
By Gregory Morrison, SVP & CIO, Cox Enterprises
By Alberto Ruocco, CIO, American Electric Power
By Sam Lamonica, CIO & VP Information Systems, Rosendin...
By Sven Gerjets, SVP-IT, DIRECTV
By Marie Blake, EVP & CCO, BankUnited
By Lowell Gilvin, Chief Process Officer, Jabil
By Walter Carvalho, VP & Corporate CIO, Carnival Corporation
By Mary Alice Annecharico, SVP & CIO, Henry Ford Health System
By Bernd Schlotter, President of Services, Unify
By Bob Fecteau, CIO, SAIC
By Jason Alan Snyder, CTO, Momentum Worldwide
By Jim Whitehurst, CEO, Red Hat
By Marc Jones, Distinguished Engineer, IBM Cloud Infrastructure